Top Research Reports for Exxon Mobil, Bristol-Myers Squibb & Chubb

Wednesday, April 2, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corp. (XOM), Bristol-Myers Squibb Co. (BMY) and Chubb Ltd. (CB), as well as a micro-cap stock Hamilton Beach Brands Holding Co. (HBB). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>>Ahead of Wall StreetThe daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.You can read today's AWS here >>> Pre-Markets Down Again on "Liberation Day"Today's Featured Research ReportsShares of Exxon Mobil have gained +3.2% over the past year, against the Zacks Oil and Gas - Integrated - International industry’s gain of +5.5%. The company’s high-value assets in the Permian Basin and Guyana drive robust production growth, doubling upstream earnings since 2019. The Pioneer acquisition and Guyana ramp-up have enhanced profitability, while robust structural savings strengthen resilience.  With a lower exposure to debt capital, XOM supports steady cash flows, dividends, buybacks and investments in high-return projects. Expansion in low-carbon tech, including Baytown's hydrogen facility, positions it for future growth.Yet refining margins are pressured due to global capacity increases, with refining profits softening. The refining margin pressure intensifies the reliance on upstream operations, which is vulnerable to fluctuating oil and gas prices. Commodity price volatility challenges profitability, especially as crude prices dipped in the fourth quarter.(You can read the full research report on Exxon Mobil here >>>)Bristol-Myers Squibb’s shares have outperformed the Zacks Medical - Biomedical and Genetics industry over the past year (+19.8% vs. -8.7%). The company’s newer drugs like Reblozyl, Breyanzi, Yervoy, Camzyos and Opdualag maintain momentum for the company. Label expansion of blockbuster oncology drug Opdivo should fuel growth. Growth in blockbuster drug Eliquis is another positive.Nevertheless, the recent acquisitions of Mirati, Karuna and RayzeBio should strengthen and diversify its portfolio. Bristol Myers’ efforts to streamline operations should boost the bottom line. The company is encouraging efforts to boost top-line growth.However, the outlook for 2025 is weak. Generic competition for Revlimid, Pomalyst, Sprycel and Abraxane is adversely impacting revenue growth.  While the performance of new drugs is encouraging, they will take some time to make a significant contribution to the top line.(You can read the full research report on Bristol-Myers Squibb here >>>)Shares of Chubb have gained +19.8% over the past year against the Zacks Insurance - Property and Casualty industry’s gain of +25.1%. The company’s suite of compelling products as well as services, focus on capitalizing on the potential of middle-market businesses and investments in various strategic initiatives pave the way for long-term growth.Several distribution agreements have expanded its network, boosting its market presence. An impressive inorganic growth story helps to achieve a higher long-term return on equity. Chubb boasts a strong capital position with sufficient cash generation capabilities that ensure steady payouts to investors.Chubb expects the quarterly adjusted net investment income to have a run rate between $1.67 billion and $1.75 billion over the next six months. However, exposure to catastrophe loss induces underwriting volatility. Escalating expenses weigh on margin expansion.(You can read the full research report on Chubb here >>>)Hamilton Beach Brands’ shares have outperformed the Zacks Household Appliances industry over the year-to-date period (+18.7% vs. -17.7%). This microcap company with market capitalization of $268.41 million achieved a record gross margin of 26% in 2024, up 300 bps year over year, driven by lower costs, improved mix and pricing discipline.Operating profit rose 23.1% to $43.2 million. A strong cash flow of $65.4 million enabled debt elimination, ending with a net cash position of $0.6 million. HBB expanded into high-margin healthcare with HealthBeacon, targeting more than 50% patient growth in 2025. Product innovation, including premium offerings and e-commerce expansion, is driving market share gains.U.S. consumer sales rose 3.6%, with strong growth in Mexico and commercial blender placements. Proactive tariff mitigation and supply-chain diversification protect margins. The 2025 guidance includes mid-single-digit revenue growth, operating profit outpacing sales and $40-$50 million in free cash flow.(You can read the full research report on Hamilton Beach Brands here >>>)Other noteworthy reports we are featuring today include Barclays PLC (BCS), Freeport-McMoRan Inc. (FCX) and Waste Connections, Inc. (WCN).Mark VickerySenior EditorNote: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>Today's Must ReadExxonMobil's (XOM) Guyana & Permian Assets Aid ProductionNew Drugs Fuel Bristol Myers (BMY) Amid Generic CompetitionBetter Pricing, New Business Growth Drive Chubb Limited (CB)Featured ReportsExploration Progress, Debt Reduction to Aid Freeport (FCX)Per the Zacks analyst, Freeport will gain from its progress in exploration activities to expand production capacity and efforts to deleverage its balance sheet amid headwinds from higher costs.nOperating Prowess Aid Waste Connections (WCN), Liquidity LowPer the Zacks analyst, Waste Connections' low-overhead, highly efficient operational structure allows it to expand into geographically contiguous markets. Low liquidity remains a concern.Strength in Cash App and Square Ecosystem Aids Block (XYZ)Per the Zacks analyst, Block is benefitting from strengthening Cash App engagement and Square ecosystem, which is contributing well to its gross payment volume.Sun Life (SLF) Gains on Solid Asia Business Amid High CostsPer the Zacks analyst, Sun Life is set for grow on solid Asia business that are expected to provide higher return and expanding global asset management business. However, high costs remain a concern.Solid Growth Across Segments, AI Integration Aid HubSpot (HUBS)Per the Zacks Analyst, HubSpot is set to benefit from solid user engagement across all segments. Management's strong focus on integrating AI capabilities across the product suites is a tailwind.DICK'S Sporting's (DKS) Sturdy Comps Run to Propel Top-LinePer the Zacks analyst, strong transactions and pricing have aided DICK'S Sporting's comps and top line. Growth stems from its omnichannel strategy, unique products, brand loyalty, and top-tier serviceBio-Techne (TECH) Banks on Growth Pillar, Macro Woes WorryThe Zacks analyst is impressed with Bio-Techne's ongoing traction in the GMP reagents business, a key part of its cell and gene therapy growth vertical. Yet, macroeconomic woes may hurt its profits.New UpgradesRestructuring, Strategic Buyouts to Support Barclays (BCS)Per the Zacks analyst, restructuring efforts to simplify business and boost operating efficiency, Tesco's retail banking operation buyout and solid balance sheet will likely aid Barclays' financials.RingCentral (RNG) Rides on Strong Portfolio, Partner BasePer the Zacks analyst, RingCentral benefits from solid demand for its Unified Communications as a Service and contact center software-as-a-service solutions.Rising Commercial and Defense Orders Aid Triumph Group (TGI)Per the Zacks analyst, Triumph Group is likely to benefit from increasing orders from its diverse customer base including commercial airplane producers and various military organizations globally.New DowngradesLow Volumes to Weigh on Caterpillar's (CAT) ResultsThe Zacks analyst is concerned that the low volume trends in two of its major segments- Construction Industries and Resource Industries will continue to hurt Caterpillar's top-line performance.Mondelez (MDLZ) Struggles With Cost Inflation, Pricing HelpsPer the Zacks analyst, Mondelez is struggling with soaring cocoa costs, currency headwinds, and margin pressure. However, strategic pricing actions help offset some inflationary challenges.Weak Residential Construction Hurts Owens Corning (OC) Per the Zacks analyst, Owens Corning business is being hurt by weak residential new construction and remodeling activities. Also, cost inflation surrounding the market is an added concern.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Exxon Mobil Corporation (XOM): Free Stock Analysis Report Barclays PLC (BCS): Free Stock Analysis Report Freeport-McMoRan Inc. (FCX): Free Stock Analysis Report Chubb Limited (CB): Free Stock Analysis Report Waste Connections, Inc. (WCN): Free Stock Analysis Report Hamilton Beach Brands Holding Company (HBB): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks